NC-BIOVENTUS
22.9.2020 16:32:10 CEST | Business Wire | Press release
Bioventus , a global leader in Innovations For Active Healing, is celebrating a milestone and recognizing more than 2 million treatments worldwide with DUROLANE , its single-injection, hyaluronic acid (HA) product used in the treatment of pain associated with osteoarthritis (OA). DUROLANE is the original single injection hyaluronic acid therapy, has helped patients in nearly 30 countries and is a trusted therapy for clinicians in the management of OA.
Proven safe and effective, DUROLANE has more clinical studies than any other US single-injection HA, and has also been proven to provide greater reduction in OA knee pain versus Synvisc-One® .1,2 It has longer lasting pain relief versus a steroid injection, is safe and repeated use of DUROLANE does not increase the incidence of adverse events.3,4
DUROLANE is available in its original 3ml syringe for treatment of large joints and in a 1ml syringe, known as DUROLANE SJ , to enable treatment of small joints.* Both are produced using a natural, safe and proven technology called NASHA® . This process yields a high molecular weight stabilized HA, which is a naturally occurring molecule that provides lubrication and cushioning in a normal joint.
“The US launch of DUROLANE in 2018 boosted our growth to more than 2 million treatments and we are very proud of this milestone. Still, there are many more patients to reach,” said John Nosenzo, Chief Commercial Officer, Bioventus. “In the US, more than 14 million people are afflicted with knee OA and osteoarthritis overall affects more than 240 million globally.5,6 Returning people to active lifestyles is our commitment to the market and we are pleased that DUROLANE is serving the needs of clinicians and the OA patients they treat.”
About Bioventus
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations For Active Healing from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com and follow the company on LinkedIn and Twitter.
Bioventus, the Bioventus logo, and DUROLANE are registered trademarks of Bioventus LLC. NASHA is a registered trademark. Synvisc-One and Synvisc are registered trademarks of Genzyme Corporation.
*DUROLANE SJ is not available in the US.
Summary of Indication for Use: DUROLANE is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacological therapy or simple analgesics, e.g. acetaminophen. Do not inject DUROLANE in patients with knee joint infections, skin diseases, or other infections in the area of the injection site. Do not administer to patients with known hypersensitivity or allergy to sodium hyaluronate preparations. Risks can include transient pain or swelling at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children. Full prescribing information can be found in product labeling, at www.DUROLANE.com , or by contacting Bioventus Customer Service at 1-800-836-4080.
NOTE: The above indications presented are for the US market; indications may vary by country. Contact your local Bioventus representative or visit www.durolane.com/uk/selection for prescribing information specific to your market.
1. McGrath AF, McGrath AM, Jessop ZM, et al. A comparison of intra-articular hyaluronic acid competitors in the treatment of mild to moderate knee osteoarthritis. J Arthritis . 2013; 2(1):108. doi:10.4172/2167-7921.1000108. 2. DOF RPT-001111 3. Leighton R, Åkermark C, Therrien R, et. al. NASHA hyaluronic acid vs methylprednisolone for knee osteoarthritis: a prospective, multi-centre, randomized, non-inferiority trial. Osteoarthritis Cartilage . 2014; 22(1):17-25. 4. DUROLANE [package insert]. Durham, NC: Bioventus LLC; 2017. 5. Arthritis Foundation. What is osteoarthritis? Accessed February 9, 2019. www.arthritis.org/about-arthritis/types/osteoarthritis/what-is-osteoarthritis.php 6. Hawker GA. Osteoarthritis is a serious disease. Clin Exp Rheumatol . 2019;37 Suppl 120(5):3-6.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200922005067/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Organon to Present New Research on Access and Value at ISPOR 202615.5.2026 13:30:00 CEST | Press release
New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women’s health and general medicines portfolio Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. Across 8 accepted abstracts, the data reflect Organon’s commitment to generating real-world evidence—rooted in lived experiences—that can help inform healthcare decision-making and improve health outcomes across a range of therapeutic areas. “Health economics and outcomes research is critical to ensuring the right treatments reach patients and that
SES Announces Extraordinary General Meeting of Shareholders15.5.2026 08:30:00 CEST | Press release
SES: Société Anonyme RCS Luxembourg B 81267 Notice is hereby given of the Extraordinary General Meeting of SES, Société Anonyme, to be held at the Company's registered office at Château de Betzdorf, L-6815 Betzdorf (the "Company"), Luxembourg, on Wednesday 17 June 2026 at 3:00 p.m. CET AGENDA Attendance list, quorum and adoption of the agenda Nomination of a secretary and of two scrutineers Cancellation of shares purchased in connection with the buy-back programme of 2 November 2023, as amended on 2 May 2024, in accordance therewith and pursuant thereto - Reduction of the share capital in accordance with article 450-5 of the law of 10 August 1915 on commercial companies, as amended, by forty-four million nine hundred ten thousand seven hundred eighty euro (EUR 44,910,780) through the cancellation of thirty-five million nine hundred and twenty-eight thousand six hundred and twenty-four (35,928,624) shares divided into (i) twenty-three million nine hundred and fifty-two thousand four hun
Experian Partners With ServiceNow to Scale Trusted Decisioning to Agentic AI15.5.2026 08:00:00 CEST | Press release
New global long‑term partnership embeds Experian’s Ascend capabilities directly into ServiceNow workflows, transforming client operations Experian, the global data and technology company, and ServiceNow (NYSE: NOW), the AI control tower for business reinvention, today unveil a new global multi-year partnership which harnesses the power of autonomous AI agents across platforms, helping businesses make faster and smarter decisions at scale. Through this partnership, autonomous AI agents can gain the ability to act faster, and more consistently, starting with employee onboarding, third-party risk management and model life cycle governance use cases. A major challenge for global organisations adopting agentic AI is achieving scale, with deployments often constrained by a lack of trusted data. In fact, industry research shows that data limitations are the primary barrier for eight in ten organisations. By connecting trusted intelligence directly into enterprise workflows, this partnership e
Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet15.5.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that the results of the Integral-1 study, one of two global Phase III clinical trials evaluating the efficacy and safety of its novel β-lactamase inhibitor nacubactam (development code: OP0595), have been published in The Lancet. The article is entitled “---Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial” (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00596-9/fulltext) Integral-1 is a global, double-blind, randomized Phase III trial (jRCT2031230075) in patients with complicated urinary tract infection or acute uncomplicated pyelonephritis that compared the efficacy and safety of nacubactam co-administered with either cefepime or aztreonam versus imipenem-c
Boomi Teams up With Gong to Bring Revenue AI to Boomi Agentstudio14.5.2026 18:00:00 CEST | Press release
Gong's revenue AI is now natively available in the Boomi Enterprise Platform Boomi, the data activation company for AI, today announced a collaboration withGong, the leader in Revenue AI, to bring revenue signals captured in Gong natively into the Boomi Enterprise Platform. This collaboration enables enterprises to establish an active data foundation designed to transform customer conversations into coordinated, automated actions across systems and functions enterprise-wide with Boomi Agentstudio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514443012/en/ Boomi Teams Up with Gong to Bring Revenue AI to Boomi Agentstudio Gong goes beyond capturing deal activity to surface real-time insights into risk, buyer intent, competitive dynamics, and key engagement signals. That intelligence moves from conversation to coordinated action, flowing across CRM, ERP, product, and operational systems with the governance and security tha
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom